GenWay Biotech obtains CLIA certification Jul 16, 2009
They have secured exclusive rights to the DR-70 test from AMDL and have secured several other biomarkers in the field of cancer diagnostics. . (EurekAlert! -- Business News)
AMDL Inc. Announces Second Closing of Private Placement of Series 2 Senior Notes Jun 16, 2009
In the first closing on May 14, 2009, AMDL sold $1,327,250 of 12% Series 2 convertible notes at par value and completed the second closing on June 12, 2009, where the Company sold $468,500 of 12% Series 2 convertible notes ... The net proceeds to AMDL from the total offering are being used to finance general working capital requirements, support product commercialization plans and reduce outstanding debt ... Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL... (PR Newswire)
AMDL, Inc. Announces First Quarter 2009 Financial Results May 17, 2009
May 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today unaudited results and the filing of its Form 10Q with the Securities and Exchange Commission ("SEC") for the first quarter ended March 31, 2009 ... AMDL has a highly seasonal business that has historically resulted in low first quarter revenues and earnings ... For the first quarter 2009 AMDL reported unaudited net revenues of approximately $2. (PR Newswire)
GenWay Biotech obtains exclusive rights to AMDL's DR-70 cancer test in US and Canada May 16, 2009
AMDL Inc. executes two exclusive distribution agreements for cancer test with GenWay Biotech Inc.. (San Diego, CA) May 15, 2009 GenWay Biotech, Inc., () a US-based diagnostic company which specializes in providing protein and antibody solutions, announced its partnership with AMDL, Inc., a US-based pharmaceutical company with major operations in China, regarding the distribution of AMDL's DR-70 (FDP) cancer test in both the United States and Canada ... Robert Gans, CEO of GenWay Biotech Inc.,... (EurekAlert! -- Business News)
AMDL, Inc. Enters Into Distribution Agreements With GenWay Biotech, Inc. to Advance Commercialization of the DR-70 (FDP) Cancer Test in the US and Canada May 14, 2009
May 13 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today it has entered into two distinct five-year marketing and distribution agreements with GenWay Biotech, Inc., a global protein and antibody solutions provider, whereby will market and distribute AMDL's DR-70 (FDP) cancer test in the US and Canada. The partnership significantly advances AMDL's global commercialization strategy for DR-70 specifically... (PR Newswire)
AMDL, Inc. Reports 2008 Year End Financial Results and Fiscal Year 2009 Financial Targets Apr 16, 2009
The significant growth in revenues was due to an increase in sales of existing products in the growing China healthcare market, which included AMDL's best-selling human placenta extract (HPE)-based skin care product, Domperidone anti-emetic drug, and other high-quality ethical pharmaceutical products ... As a percentage of net revenues, gross profits declined slightly due to a change in AMDL's product mix, which shifted away from certain products reliant on a non-operating small injectable... (PR Newswire)
